论文部分内容阅读
100例局限期(LD)小细胞肺癌(SCLC),用COM、COF、COM-Cc(COF-Cc)或COM-Cc-VP诱导化疗,继以局部放疗和/或脑预防放疗(PBI),并继续化疗,争取总治程达2年。CR 40％(40/100)、CR+PR 94％(94/100)。中数生存期16月,达CR者21月。2、3、5年生存期概率分别为43％、33％及23％。现6例>5-9年仍生存,3例已34—41月仍CR中,1例CR者于81月死于急性心肌梗塞。3药与≥4药诱导化疗疗效、年生存率、年缓解率无差别。CR者之2、3、5年生存率,及缓解率均优于PR者。诱导化疗并局部放疗后,继续化疗>6次(约24周)者:CR者的2、3年生存率,及PR者之1、2年生存率,均显著优于≤6次化疗者(P<0.01、<0.01,70.05、<0.05)。PBI者脑转移率与PBI(-)者无差别,但MST、2、3年生存率优于PBI(-)者(P<0.005、<0.001、<0.005)。Zubrod ECOG—WHO全身状况计分0—1者,CR、CR+PR及2、3、5年生存期,均显著优于2—3分者(P<0.01、<0.01、=0.003、=0.004及=0.02)。性别对疗效、生存率无影响。本组毒性均轻到中度,无与化疗有关之死亡。
100 patients with limited-stage (LD) small-cell lung cancer (SCLC) were treated with COM, COF, COM-Cc (COF-Cc), or COM-Cc-VP, followed by local radiation therapy and/or brain preventive radiation therapy (PBI). And continue chemotherapy, for a total governance of up to 2 years. CR 40% (40/100), CR+PR 94% (94/100). The median survival period was 16 months, reaching CR in 21 months. The survival probabilities of 2, 3, and 5 years were 43%, 33%, and 23%, respectively. Six patients were still living >5-9 years, 3 patients were still CR in 34-41 months, and one CR patient died of acute myocardial infarction in August. There was no difference in efficacy, annual survival rate, and annual remission rate between 3 drugs and ≥ 4 drug-induced chemotherapy. The CR survival rate of 2, 3, and 5 years, and remission rate were better than those of PR. After induction chemotherapy and local radiotherapy, patients who continued chemotherapy for more than 6 cycles (about 24 weeks): 2-year and 3-year survival rates of CR patients, and 1- and 2-year survival rates of PR patients were significantly better than ≤6 chemotherapy users ( P<0.01, <0.01, 70.05, <0.05). There was no difference in PBI brain metastasis rate with PBI(-), but the survival rate of MST, 2 and 3 years was better than that of PBI(-) (P<0.005, <0.001, <0.005). Zubrod ECOG-WHO scored 0-1 for general condition, CR, CR+PR and 2, 3, and 5-year survival period were all significantly better than 2-3 (P<0.01, <0.01, 0.003, 0.003). And = 0.02). Gender has no effect on efficacy or survival. The toxicity of this group was mild to moderate, and there was no chemotherapy-related death.